Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« Proton-pump inhibitors may reduce benefits of atezolizumab in urothelial carcinoma Next Article
Ertugliflozin passes post-approval cardiovascular safety test »
« Proton-pump inhibitors may reduce benefits of atezolizumab in urothelial carcinoma Next Article
Ertugliflozin passes post-approval cardiovascular safety test »
Related Articles
March 21, 2022
Impact of COVID-19 on screening for colorectal cancer
November 30, 2021
Study reveals spectrum of COVID-19 brain complications
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy